Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes
IMPORTANCE: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. OBJECTIVE:...
Gespeichert in:
Veröffentlicht in: | JAMA psychiatry (Chicago, Ill.) Ill.), 2017-06, Vol.74 (6), p.597-603 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 603 |
---|---|
container_issue | 6 |
container_start_page | 597 |
container_title | JAMA psychiatry (Chicago, Ill.) |
container_volume | 74 |
creator | Chang, Zheng Quinn, Patrick D Hur, Kwan Gibbons, Robert D Sjolander, Arvid Larsson, Henrik D’Onofrio, Brian M |
description | IMPORTANCE: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. OBJECTIVE: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. DESIGN, SETTING, AND PARTICIPANTS: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. EXPOSURES: Dispensed prescription of ADHD medications. MAIN OUTCOMES AND MEASURES: Emergency department visits for MVCs. RESULTS: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. CONCLUSIONS AND RELEVANCE: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity. |
doi_str_mv | 10.1001/jamapsychiatry.2017.0659 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_496888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2626505</ama_id><sourcerecordid>1925418580</sourcerecordid><originalsourceid>FETCH-LOGICAL-a542t-d7e7fdaec865336dc4d8041d259e1d364056b5538a186a40ee8acfbec9aa2bf3</originalsourceid><addsrcrecordid>eNp1kt9rFDEQxxdRbKn9B3yQgC8-uNf82GSzL8J5p1ZoEaQW30IuO9vLdW9zTbIt-9-bZc_TEwyEDJPPfJkZvlmGCJ4RjMnFRm_1LgxmbXX0w4xiUs6w4NWz7JQSIXNBmXx-iOnPk-w8hA1OR2JcMPkyO6GyqGjFytPsYR6CM0nJug59hPgE0KFrqK2ZUj8CoMZ5NI8RujGTL6GxxsaLy2EHXptoH20c0NIG52vwSHc1-m7DPXINunYxld7C2poW0MLrsIbwKnvR6DbA-f49y24-f7pZXOZX3758Xcyvcs0LGvO6hLKpNRgpOGOiNkUtcUFqyisgNRMF5mLFOZOaSKELDCC1aVZgKq3pqmFnWT7JhifY9Su183ar_aCctmqfuk8RqKISUsrEv_8vv7S3c-X8Xbq94rKUPOEfJjyxW6hNWo7X7VHV8U9n1-rOParUciULnATe7QW8e-ghRLW1wUDb6g5cHxSRVZkGZnhs7e0_6Mb1vkvLU6SivCCSy1FQTpTxLgQPzaEZgtVoHHVsHDUaR43GSaVv_h7mUPjbJgl4PQFJ4c-voIJjzn4BOIjP_Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925418580</pqid></control><display><type>article</type><title>Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes</title><source>MEDLINE</source><source>American Medical Association Journals</source><source>SWEPUB Freely available online</source><creator>Chang, Zheng ; Quinn, Patrick D ; Hur, Kwan ; Gibbons, Robert D ; Sjolander, Arvid ; Larsson, Henrik ; D’Onofrio, Brian M</creator><creatorcontrib>Chang, Zheng ; Quinn, Patrick D ; Hur, Kwan ; Gibbons, Robert D ; Sjolander, Arvid ; Larsson, Henrik ; D’Onofrio, Brian M</creatorcontrib><description>IMPORTANCE: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. OBJECTIVE: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. DESIGN, SETTING, AND PARTICIPANTS: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. EXPOSURES: Dispensed prescription of ADHD medications. MAIN OUTCOMES AND MEASURES: Emergency department visits for MVCs. RESULTS: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. CONCLUSIONS AND RELEVANCE: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.</description><identifier>ISSN: 2168-622X</identifier><identifier>ISSN: 2168-6238</identifier><identifier>EISSN: 2168-6238</identifier><identifier>DOI: 10.1001/jamapsychiatry.2017.0659</identifier><identifier>PMID: 28492937</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Accidents, Traffic - prevention & control ; Accidents, Traffic - statistics & numerical data ; Adult ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - epidemiology ; Attention deficit hyperactivity disorder ; Central Nervous System Stimulants - adverse effects ; Central Nervous System Stimulants - therapeutic use ; Cohort Studies ; Collisions ; Cross-Sectional Studies ; Drug use ; Emergency Service, Hospital - statistics & numerical data ; Female ; Follow-Up Studies ; Health insurance ; Humans ; Insurance claims ; Male ; Middle Aged ; Online First ; Original Investigation ; Psychiatry ; Psykiatri ; Risk ; Risk factors ; Statistics as Topic ; United States ; Utilization Review - statistics & numerical data</subject><ispartof>JAMA psychiatry (Chicago, Ill.), 2017-06, Vol.74 (6), p.597-603</ispartof><rights>Copyright American Medical Association Jun 2017</rights><rights>Copyright 2017 American Medical Association. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a542t-d7e7fdaec865336dc4d8041d259e1d364056b5538a186a40ee8acfbec9aa2bf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/articlepdf/10.1001/jamapsychiatry.2017.0659$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2017.0659$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,230,314,550,776,780,881,3327,27901,27902,76231,76234</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28492937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-58785$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:135987362$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Zheng</creatorcontrib><creatorcontrib>Quinn, Patrick D</creatorcontrib><creatorcontrib>Hur, Kwan</creatorcontrib><creatorcontrib>Gibbons, Robert D</creatorcontrib><creatorcontrib>Sjolander, Arvid</creatorcontrib><creatorcontrib>Larsson, Henrik</creatorcontrib><creatorcontrib>D’Onofrio, Brian M</creatorcontrib><title>Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes</title><title>JAMA psychiatry (Chicago, Ill.)</title><addtitle>JAMA Psychiatry</addtitle><description>IMPORTANCE: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. OBJECTIVE: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. DESIGN, SETTING, AND PARTICIPANTS: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. EXPOSURES: Dispensed prescription of ADHD medications. MAIN OUTCOMES AND MEASURES: Emergency department visits for MVCs. RESULTS: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. CONCLUSIONS AND RELEVANCE: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.</description><subject>Accidents, Traffic - prevention & control</subject><subject>Accidents, Traffic - statistics & numerical data</subject><subject>Adult</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - epidemiology</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Central Nervous System Stimulants - adverse effects</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Cohort Studies</subject><subject>Collisions</subject><subject>Cross-Sectional Studies</subject><subject>Drug use</subject><subject>Emergency Service, Hospital - statistics & numerical data</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health insurance</subject><subject>Humans</subject><subject>Insurance claims</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Online First</subject><subject>Original Investigation</subject><subject>Psychiatry</subject><subject>Psykiatri</subject><subject>Risk</subject><subject>Risk factors</subject><subject>Statistics as Topic</subject><subject>United States</subject><subject>Utilization Review - statistics & numerical data</subject><issn>2168-622X</issn><issn>2168-6238</issn><issn>2168-6238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp1kt9rFDEQxxdRbKn9B3yQgC8-uNf82GSzL8J5p1ZoEaQW30IuO9vLdW9zTbIt-9-bZc_TEwyEDJPPfJkZvlmGCJ4RjMnFRm_1LgxmbXX0w4xiUs6w4NWz7JQSIXNBmXx-iOnPk-w8hA1OR2JcMPkyO6GyqGjFytPsYR6CM0nJug59hPgE0KFrqK2ZUj8CoMZ5NI8RujGTL6GxxsaLy2EHXptoH20c0NIG52vwSHc1-m7DPXINunYxld7C2poW0MLrsIbwKnvR6DbA-f49y24-f7pZXOZX3758Xcyvcs0LGvO6hLKpNRgpOGOiNkUtcUFqyisgNRMF5mLFOZOaSKELDCC1aVZgKq3pqmFnWT7JhifY9Su183ar_aCctmqfuk8RqKISUsrEv_8vv7S3c-X8Xbq94rKUPOEfJjyxW6hNWo7X7VHV8U9n1-rOParUciULnATe7QW8e-ghRLW1wUDb6g5cHxSRVZkGZnhs7e0_6Mb1vkvLU6SivCCSy1FQTpTxLgQPzaEZgtVoHHVsHDUaR43GSaVv_h7mUPjbJgl4PQFJ4c-voIJjzn4BOIjP_Q</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Chang, Zheng</creator><creator>Quinn, Patrick D</creator><creator>Hur, Kwan</creator><creator>Gibbons, Robert D</creator><creator>Sjolander, Arvid</creator><creator>Larsson, Henrik</creator><creator>D’Onofrio, Brian M</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D91</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20170601</creationdate><title>Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes</title><author>Chang, Zheng ; Quinn, Patrick D ; Hur, Kwan ; Gibbons, Robert D ; Sjolander, Arvid ; Larsson, Henrik ; D’Onofrio, Brian M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a542t-d7e7fdaec865336dc4d8041d259e1d364056b5538a186a40ee8acfbec9aa2bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Accidents, Traffic - prevention & control</topic><topic>Accidents, Traffic - statistics & numerical data</topic><topic>Adult</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - epidemiology</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Central Nervous System Stimulants - adverse effects</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Cohort Studies</topic><topic>Collisions</topic><topic>Cross-Sectional Studies</topic><topic>Drug use</topic><topic>Emergency Service, Hospital - statistics & numerical data</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health insurance</topic><topic>Humans</topic><topic>Insurance claims</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Online First</topic><topic>Original Investigation</topic><topic>Psychiatry</topic><topic>Psykiatri</topic><topic>Risk</topic><topic>Risk factors</topic><topic>Statistics as Topic</topic><topic>United States</topic><topic>Utilization Review - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Zheng</creatorcontrib><creatorcontrib>Quinn, Patrick D</creatorcontrib><creatorcontrib>Hur, Kwan</creatorcontrib><creatorcontrib>Gibbons, Robert D</creatorcontrib><creatorcontrib>Sjolander, Arvid</creatorcontrib><creatorcontrib>Larsson, Henrik</creatorcontrib><creatorcontrib>D’Onofrio, Brian M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Örebro universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Zheng</au><au>Quinn, Patrick D</au><au>Hur, Kwan</au><au>Gibbons, Robert D</au><au>Sjolander, Arvid</au><au>Larsson, Henrik</au><au>D’Onofrio, Brian M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes</atitle><jtitle>JAMA psychiatry (Chicago, Ill.)</jtitle><addtitle>JAMA Psychiatry</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>74</volume><issue>6</issue><spage>597</spage><epage>603</epage><pages>597-603</pages><issn>2168-622X</issn><issn>2168-6238</issn><eissn>2168-6238</eissn><abstract>IMPORTANCE: Motor vehicle crashes (MVCs) are a major public health problem. Research has demonstrated that individuals with attention-deficit/hyperactivity disorder (ADHD) are more likely to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear. OBJECTIVE: To explore associations between ADHD medication use and risk of MVCs in a large cohort of patients with ADHD. DESIGN, SETTING, AND PARTICIPANTS: For this study, a US national cohort of patients with ADHD (n = 2 319 450) was identified from commercial health insurance claims between January 1, 2005, and December 31, 2014, and followed up for emergency department visits for MVCs. The study used within-individual analyses to compare the risk of MVCs during months in which patients received ADHD medication with the risk of MVCs during months in which they did not receive ADHD medication. EXPOSURES: Dispensed prescription of ADHD medications. MAIN OUTCOMES AND MEASURES: Emergency department visits for MVCs. RESULTS: Among 2 319 450 patients identified with ADHD, the mean (SD) age was 32.5 (12.8) years, and 51.7% were female. In the within-individual analyses, male patients with ADHD had a 38% (odds ratio, 0.62; 95% CI, 0.56-0.67) lower risk of MVCs in months when receiving ADHD medication compared with months when not receiving medication, and female patients had a 42% (odds ratio, 0.58; 95% CI, 0.53-0.62) lower risk of MVCs in months when receiving ADHD medication. Similar reductions were found across all age groups, across multiple sensitivity analyses, and when considering the long-term association between ADHD medication use and MVCs. Estimates of the population-attributable fraction suggested that up to 22.1% of the MVCs in patients with ADHD could have been avoided if they had received medication during the entire follow-up. CONCLUSIONS AND RELEVANCE: Among patients with ADHD, rates of MVCs were lower during periods when they received ADHD medication. Considering the high prevalence of ADHD and its association with MVCs, these findings warrant attention to this prevalent and preventable cause of mortality and morbidity.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>28492937</pmid><doi>10.1001/jamapsychiatry.2017.0659</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-622X |
ispartof | JAMA psychiatry (Chicago, Ill.), 2017-06, Vol.74 (6), p.597-603 |
issn | 2168-622X 2168-6238 2168-6238 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_496888 |
source | MEDLINE; American Medical Association Journals; SWEPUB Freely available online |
subjects | Accidents, Traffic - prevention & control Accidents, Traffic - statistics & numerical data Adult Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - epidemiology Attention deficit hyperactivity disorder Central Nervous System Stimulants - adverse effects Central Nervous System Stimulants - therapeutic use Cohort Studies Collisions Cross-Sectional Studies Drug use Emergency Service, Hospital - statistics & numerical data Female Follow-Up Studies Health insurance Humans Insurance claims Male Middle Aged Online First Original Investigation Psychiatry Psykiatri Risk Risk factors Statistics as Topic United States Utilization Review - statistics & numerical data |
title | Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T09%3A30%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20Between%20Medication%20Use%20for%20Attention-Deficit/Hyperactivity%20Disorder%20and%20Risk%20of%20Motor%20Vehicle%20Crashes&rft.jtitle=JAMA%20psychiatry%20(Chicago,%20Ill.)&rft.au=Chang,%20Zheng&rft.date=2017-06-01&rft.volume=74&rft.issue=6&rft.spage=597&rft.epage=603&rft.pages=597-603&rft.issn=2168-622X&rft.eissn=2168-6238&rft_id=info:doi/10.1001/jamapsychiatry.2017.0659&rft_dat=%3Cproquest_swepu%3E1925418580%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925418580&rft_id=info:pmid/28492937&rft_ama_id=2626505&rfr_iscdi=true |